TTR and amyloidosis: In 2021, promising results were published from a phase I, in vivo, CRISPR-Cas9-based gene-editing clinical trial in transthyretin (TTR) amyloidosis, in which progressive potentially fatal damage occurs due to the deposition of misfolded TTR protein in nerves and the heart.